PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

Size: px
Start display at page:

Download "PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne"

Transcription

1 Public consultation on Delegated Act on Post-Authorisation efficacy studies PGEU RESPONSE

2 INTRODUCTION The Pharmaceutical Group of the European Union (PGEU) is the association representing community pharmacists in 32 European countries. In Europe over community pharmacists provide services throughout a network of more than pharmacies, to an estimated 46 million European citizens daily. PGEU s objective is to promote the role of pharmacists as key players in healthcare systems throughout Europe and to ensure that the views of the pharmacy profession are taken into account in the EU decision-making process. PGEU welcomes this consultation paper to support the Commission in further exploring the application of a delegated act to post-authorisation efficacy studies (PAES), which complement efficacy data available at the initial authorisation stage, for the purpose of ensuring public health protection in the EU. In this context, PGEU recalls the important role the European network of pharmacies may play in collaborating with Authorities and Marketing Authorisation Holders (MAH) to collect post-authorisation real-world data, both for safety, and for effectiveness studies. Community pharmacies are the most accessible health care facility to the general public where highly qualified healthcare professionals provide a wide range of professional services to EU citizens. The public health mission of community pharmacists goes far beyond the use of medicines. It is part of a broader public health strategy focusing on the population, and aims to improve the health status and quality of life. Additionally, 99.99% of the European pharmacies are computerized and equipped with information systems that support dispensing, but often include other features as well, such as tracking medication history in an electronic patient record. The unique position of community pharmacies, at the heart of communities and very often the first and last point of the patient s interaction with health system, represent a unique research opportunities. Pharmacies can collect medicines use as well as patient experience data and assist National Authorities and MAH, for the purpose of a truly pro-active and systematic pharmacovigilance throughout the entire life cycle of the medicines, in the public health interest. Consultation Item No 1: Do you think that a delegated act on the situations in which a post authorisation efficacy study may be required will be of added value and that the Commission should consider bringing forward a draft delegated act? Please provide reasons for your opinion. Yes. The possibility for the Commission to adopt this delegated act and establish clear reference points for situations in which these studies may be required is in the interest of public health and will bring further regulatory clarity. However it is important to implement this provision with caution so it is not abused, when for example bringing products that do not have well established safety profile on the market, before answering all the necessary concerns. We hope that transparency would be the key issue in all post-authorisation studies conducted in the EU. Unequivocally, society demands a transparent and

3 an integrated assessment of benefits and risks, under real life conditions, as the next logical step after clinical trials. Consultation Item No 2: Do you have any comments on the above? Do you agree that generally speaking post-authorisation efficacy studies should focus on generating efficacy data? It is well recognized the existing gap between efficacy and effectiveness. Addressing efficacy studies alone poses a problem of how well the real world patient population of a particular medicine is represented in efficacy studies, especially in situations that might have a negative impact on effectiveness and that may only be captured in large and real world samples (e.g. wide prescribing variations, off-label prescribing, prescribing far outside guidelines, co-morbidities, polypharmacy, adherence and persistence severe issues, etc). The discussion around making use of a delegated act in the public health interest should not be a discussion between two methodologies. Both efficacy and effectiveness post-authorisation studies are important and complement one another. Therefore, PGEU supports the need not to exclude both strategies from the delegated act set out for reference standards for PAES studies. Instead, the emphasis should be made at sound and robust epidemiological and statistical methods for both designs and for the important role of both efficacy and effectiveness studies. On the other hand, risk should not be neglected. When considering how to maximize or indeed assess the risk-benefit balance the paramount of medicines evaluation risks need to be understood in the context of benefit. Consultation Item No 3: Please comment on the seven different situations described above. Do you agree that in these situations, a competent authority may ask for a post-authorisation efficacy study? Are there any other situations not covered by points 5.1 to 5.7 in which it would also be justified to oblige a marketing authorisation holder to conduct an efficacy study? If this is the case, could you please elaborate on these situations, if possible, give pscific examples to underpin the need? Yes, all of the outlined seven situations may be considered possible PAES scenarios requested by a competent authority. In the context of the different situations described in the concept paper, PGEU would like to point out two situations where European community pharmacies may play key role in collaboration with Authorities and Marketing Authorisation Holders (MAH) to collect post-authorisation real-world data. Studies in sub-populations Several sub-populations are not included in RCTs that lead to the marketing authorisation. Paediatric and geriatric populations are two most evident examples. In addition, aging European population and increasing proportion of the elderly together with co-morbidities, polipharmacy, adherence / persistence Page 3 of 5

4 issues, etc, that are typical to this sub-population, substantially increases the probability of important deviations to the benefit/risk profile, when comparing RCT populations vs real-world populations. The threshold for investigating both safety and efficacy concerns in specific populations further will depend upon the indication, the target population, and the likely impact on public health. Requests from EMA or from the National Agency in the initial MA or later on shall be a reality. The accessibility, wide distribution, the expertise on medicines and the relationship based on trust between patients and pharmacists make community pharmacies a key player for collecting data for studies in sub-populations. For these reasons, community pharmacists come in contact with a broad range of the population, without selection criteria such as those used in RCT, and thus, the community pharmacies are better positioned to identify patients and collect real data for post-authorisation studies in all the types of sub-populations. Studies in everyday medical practice This is particularly important for patients affected by chronic diseases where there is a perceived strong gap between efficacy demonstrated in RCTs and effectiveness under real life conditions. It is often due to different real patient population, wrong patient selection, prescribing patterns, off-label prescribing, prevailing prescribing patterns outside guidelines, comorbidities/polypharmacy, patient adherence/persistence and utilisation severe issues, etc. People with chronic diseases managed by medication visit their community pharmacists more frequently than any other healthcare professional. Thus, European community pharmacists are well aware of the problems, experiences and outcomes of these patients. As stated, vaccines are also another example where the need for assessing the effectiveness is crucial. Here, medicine utilisation data represents a vehicle to enhance regulatory dialogue. Medicine utilisation research is an eclectic discipline, integrating descriptive and analytical methods for the quantification, the understanding and the evaluation of the processes of prescribing, dispensing and consumption of medicines; and for the testing of interventions to enhance the quality of these processes. In this field, pharmacoepidemiology as a discipline has a key role on understanding the evidence base and interpreting data on drug utilization. Evaluation of external validity of published clinical trials data by comparing its data to observational data obtained from clinical daily practice in EU should not be neglected. Consultation Item No 4: Do you have any comments on the above? As previously stated, the delegated act should not elaborate, in our point of view, on methodological issues for PAES design, as these are progressing over time. It should not adopt a preference stand for interventional studies, as outlined. Instead, it should recommend that both efficacy and effectiveness are addressed in future PAES, calling for robust methods. We suggest that methodological standards defined by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) should be recommended for these studies. Page 4 of 5

5 Furthermore, considering the importance of the patient as a key player in pharmacovigilance systems, already recognized in the directive, PGEU believes that patients role should also be considered under the delegated act on PAES. It is expected that patient preferences and patient reported outcomes will become more important for marketing authorization purposes. As the validity and reliability of such metrics tend to improve, it is important to allow PAES that include a Patient Reported Outcomes (PRO). Finally, although out of the scope of the Pharmacovigilance Directive, PGEU believes that the EC may take this opportunity to address economic and financial issues related to medicine utilisation. Several factors put national health systems under pressure, such as demographic, economic and changing risk factors to health. Thus, the situations in which pharmacoeconomics studies and medicine utilisation studies in compliance with existent clinical and prescribing guidelines adopted at National level may be needed, can also be assessed and discussed at European level. These studies are an essential tool to promote public health, cost-effectiveness of the treatments and sustainability of the national health systems. For example, certain medicines are second and third line therapies (when patients do not respond to the first line therapy) and, hence, were authorised for a particular patient subgroup or condition. However, prescribing influence by marketing authorization holders (marketing bias) may have an impact in widening the use of the medicine in the real world setting to a broader population and scope of conditions. Often, the first sign is the increasing consumption pattern of the new medicine vs expected patterns based on approved indication. Studies linked to increasing consumption of medicines which are not first line therapies and/or indications limited to a patient subgroup or in a restricted condition, are one example of a situation that can contribute to a better use of medicines and to reduce costs both for patients and for States. In conclusion, community pharmacies in Europe are ready to collaborate with the National Authorities, in implementing an effective pharmacovigilance system throughout the entire life cycle of the medicines, in the public health interest. Community pharmacists are prepared to assume more responsibility and intervene in post-authorisation studies for pharmacoviligance, pharmacoeconomics and pharmacoepidemiological purposes. Page 5 of 5

BACKGROUND + GENERAL COMMENTS

BACKGROUND + GENERAL COMMENTS Response on behalf of Sobi (Swedish Orphan Biovitrum AB) to the European Commission s Public Consultation on a Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No. 141/2000

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA Ref. Ares(2012)1405774-28/11/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA DELEGATED ACT ON POST-AUTHORISATION EFFICACY

More information

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State Ref:11.11.24E 007 PGEU Response Consultation on measures for improving the recognition of medical prescriptions issued in another Member State PGEU The Pharmaceutical Group of the European Union (PGEU)

More information

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 19 April 2013 EMA/169546/2012 Guideline on good pharmacovigilance practices (GVP) Module X Additional monitoring Draft finalised by the Agency in collaboration with Member States 25 May 2012 Draft agreed

More information

Secretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director

Secretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director COUNCIL OF THE EUROPEAN UNION Brussels, 13 February 2014 (OR. en) 6438/14 COVER NOTE From: date of receipt: 3 February 2014 To: No. Cion doc.: PHARM 14 SAN 72 MI 161 COMPET 107 DELACT 29 Secretary-General

More information

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products 25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of

More information

The Danish Medicines Agency s availability strategy

The Danish Medicines Agency s availability strategy låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images

More information

Pharmacovigilance Methods and Post-Authorisation Safety Studies

Pharmacovigilance Methods and Post-Authorisation Safety Studies Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module

More information

The Committee for Medicinal Products for Human Use

The Committee for Medicinal Products for Human Use www.eurordis.org The Committee for Medicinal Products for Human Use Patrick Salmon HPRA Barcelona, 4th June, 2015 2 CHMP 3 CHMP Move 4 The New CHMP 5 Where it all happens! 6 CHMP... What is it? CHMP What

More information

Other EU Activities Contributing to Harmonization of Labeling

Other EU Activities Contributing to Harmonization of Labeling Other EU Activities Contributing to Harmonization of Labeling Dr Laurent Brassart European Medicines Agency Medical Information Sector DIA Labeling Harmonisation 2011 Workshop October 13-14. 2011 Disclaimer

More information

The Paediatric Regulation a perspective from the European Medicines Agency

The Paediatric Regulation a perspective from the European Medicines Agency The Paediatric Regulation a perspective from the European Medicines Agency Dr Edith La Mache EMEA Current paediatric situation 20% of the EU population, i.e. 100 million, is aged less than 16 years premature

More information

Access to newly licensed medicines. Scottish Medicines Consortium

Access to newly licensed medicines. Scottish Medicines Consortium Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also

More information

PRAC non-interventional imposed PASS final study report assessment report

PRAC non-interventional imposed PASS final study report assessment report 1 December 2016 EMA/101726/2017 Pharmacovigilance Risk Assessment Committee (PRAC) PRAC non-interventional imposed PASS final study report assessment report Cyproterone/ethinylestradiol Active substance:

More information

SUMMARY OF THE REPLIES

SUMMARY OF THE REPLIES Ref. Ares(2013)36608-14/01/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, SANCO/D5/FS/ci D(2013) 27105 GENERAL

More information

Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the

Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC Submitted by the European AIDS Treatment

More information

1. Introduction. 2. Role of PSI as Pharmacy Regulator

1. Introduction. 2. Role of PSI as Pharmacy Regulator 1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal

More information

Working Document prepared by the Commission services - does not prejudice the Commission's final decision 3/2/2014 COMMISSION STAFF WORKING DOCUMENT

Working Document prepared by the Commission services - does not prejudice the Commission's final decision 3/2/2014 COMMISSION STAFF WORKING DOCUMENT COMMISSION STAFF WORKING DOCUMENT on certain requirements for FSMPs [Supporting Document for the Expert Group meeting of 7 February 2014] Introduction Following the discussions in the Expert Group meeting

More information

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015 EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, European Medicines Agency PHARM 689 PHARMACEUTICAL COMMITTEE 21 October 2015

More information

SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH. (Section GM Food & Feed and Environmental Risk)

SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH. (Section GM Food & Feed and Environmental Risk) SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 19 APRIL 2007 (Section GM Food & Feed and Environmental Risk) President for items 1-3: Dorothée André President

More information

Changing practice to support service delivery

Changing practice to support service delivery Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction

More information

Case scenarios: Patient Group Directions

Case scenarios: Patient Group Directions Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios

More information

The RPS is the professional body for pharmacists in Wales and across Great Britain. We are the only body that represents all sectors of pharmacy.

The RPS is the professional body for pharmacists in Wales and across Great Britain. We are the only body that represents all sectors of pharmacy. Royal Pharmaceutical Society 2 Ash Tree Court Woodsy Close Cardiff Gate Business Park Pontprennau Cardiff CF23 8RW Mr Mark Drakeford AM, Chair, Health and Social Care Committee National Assembly for Wales

More information

(Legislative acts) REGULATIONS

(Legislative acts) REGULATIONS 31.12.2010 Official Journal of the European Union L 348/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards

More information

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM

More information

EU Regulatory Requirements Update, the latest news and developments. Hans-Heiner Junker TÜV SÜD Product Service GmbH October 2013

EU Regulatory Requirements Update, the latest news and developments. Hans-Heiner Junker TÜV SÜD Product Service GmbH October 2013 EU Regulatory Requirements Update, the latest news and developments Hans-Heiner Junker TÜV SÜD Product Service GmbH October 2013 Folie 1 Content Two groups of Notified Bodies Designation process with European

More information

Guideline on influenza vaccines submission and procedural requirements

Guideline on influenza vaccines submission and procedural requirements 1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES

More information

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus

More information

The Committee for Medicinal Products for Human Use

The Committee for Medicinal Products for Human Use www.eurordis.org The Committee for Medicinal Products for Human Use Patrick Salmon IMB Barcelona, 20 June, 2013 2 EURORDIS SUMMER SCHOOL 2013 CHMP CHMP... What is it? 3 EURORDIS SUMMER SCHOOL 2013 CHMP

More information

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009 15 March 2010 EMA/CVMP/IWP/105506/2007 Committee for medicinal products for veterinary use (CVMP) Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza

More information

Holders of European Union marketing authorizations

Holders of European Union marketing authorizations PRAC Experience The legal framework The Pharmacovigilance legislation (Regulation No 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December 2010. The

More information

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017 1 2 3 7 September 2017 EMA/CVMP/IWP/105506/2007-Rev.1 Committee for medicinal products for veterinary use (CVMP) 4 5 6 7 Guideline on data requirements for multi-strain dossiers for inactivated vaccines

More information

C 178/2 Official Journal of the European Union

C 178/2 Official Journal of the European Union C 178/2 Official Journal of the European Union 29.7.2003 Communication from the Commission on Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products (2003/C

More information

REGULATION (EC) No.141/2000

REGULATION (EC) No.141/2000 REGULATION (EC) No.141/2000 Community legislation in force Document 300R0141 Directory chapters where this document can be found: [15.30 Health promotion] Regulation (EC) No.141/2000 of the European Parliament

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Reflection paper on assessment of cardiovascular safety profile of medicinal products 25 February 2016 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on assessment of cardiovascular safety profile of medicinal products Draft agreed by Cardiovascular

More information

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Reflection paper on the use of extrapolation in the development of medicines for paediatrics

Reflection paper on the use of extrapolation in the development of medicines for paediatrics 7 October 2018 EMA/189724/2018 Reflection paper on the use of extrapolation in the development of medicines for paediatrics Final Draft agreed by Biostatistics Working Party, Modelling and Simulation September

More information

Statement regarding: Key ideas of a draft legal proposal on information to patients by the European Commission (DG Enterprise and Industry)

Statement regarding: Key ideas of a draft legal proposal on information to patients by the European Commission (DG Enterprise and Industry) STATEMENT 7 April 2008 European Commission Statement regarding: Key ideas of a draft legal proposal on information to patients by the European Commission (DG Enterprise and Industry) 1. Background history,

More information

The Nutrition (Amendment) (EU Exit) Regulations 2018

The Nutrition (Amendment) (EU Exit) Regulations 2018 The Nutrition (Amendment) (EU Exit) Regulations 2018 A public consultation Contents Introduction... 3 Why we are consulting... 4 Nutrition and Health Claims... 6 Proposals... 6 Vitamins, minerals, and

More information

Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015

Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 Introduction Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 From September 2015 the All Wales Medicines Strategy

More information

COUNCIL RECOMMENDATION of 2 December 2003 on cancer screening (2003/878/EC)

COUNCIL RECOMMENDATION of 2 December 2003 on cancer screening (2003/878/EC) L 327/34 COUNCIL RECOMMDATION of 2 December 2003 on cancer screening (2003/878/EC) THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular

More information

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the

More information

CABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND

CABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:

More information

Annex IV Scientific conclusions

Annex IV Scientific conclusions Annex IV Scientific conclusions 56 Scientific conclusions On 7 June 2017, the European Commission (EC) was informed of a fatal case of fulminant liver failure in a patient treated with daclizumab in an

More information

CHAPTER 3. Union Referral Procedures MAY 2014

CHAPTER 3. Union Referral Procedures MAY 2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Brussels, Revision May 2014 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation

More information

ATMPs & EU GMP Update. Bryan J Wright July 2017

ATMPs & EU GMP Update. Bryan J Wright July 2017 ATMPs & EU GMP Update Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline ATMPs What they are? Why are we looking at this subject? The Licensing position of ATMPs and use of PRIME ATMPs and GMP Inspections

More information

Allergy Therapeutics Ltd. Comments on:

Allergy Therapeutics Ltd. Comments on: Allergy Therapeutics Ltd. Comments on: Delegated act on the detailed rules for a unique identifier for medicinal products for human use, and its verification Concept paper submitted for public consultation

More information

Review of Controlled Drugs and Substances Act

Review of Controlled Drugs and Substances Act Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A

More information

STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW. Summary Record of Meeting of 30 April 2012

STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW. Summary Record of Meeting of 30 April 2012 EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW Summary Record of Meeting of 30 April 2012 Chairmen: Mr Basil

More information

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure 1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza

More information

Research Topics. ENCePP Plenary Survey (April 2011) An agency of the European Union

Research Topics. ENCePP Plenary Survey (April 2011) An agency of the European Union Research Topics ENCePP Plenary Survey (April 2011) An agency of the European Union Q: Can you suggest any research topics that you would like to see included in public funding programmes? More than 40

More information

ROADMAP TO REVIEW THE NUTRITION AND HEALTH CLAIMS REGULATION 1924/2006 Food Supplements Europe Comments

ROADMAP TO REVIEW THE NUTRITION AND HEALTH CLAIMS REGULATION 1924/2006 Food Supplements Europe Comments ROADMAP TO REVIEW THE NUTRITION AND HEALTH CLAIMS REGULATION 1924/2006 Food Supplements Europe Comments 1. Food Supplements Europe Food Supplements Europe represents the interests of the EU food supplement

More information

CONTRIBUTION TO THE CONSULTATION ON THE FUTURE "EU 2020" STRATEGY

CONTRIBUTION TO THE CONSULTATION ON THE FUTURE EU 2020 STRATEGY AUTISM-EUROPE Rue Montoyer 39 bte11, 1000 Bruxelles ~ Belgique tél. +32(0)2-675.75.05 - fax +32 (0)2-675.72.70 E-mail: secretariat@autismeurope.org Web Site: www.autismeurope.org AUTISME-EUROPE aisbl CONTRIBUTION

More information

The European Medicines Agency (EMA)

The European Medicines Agency (EMA) The European Medicines Agency (EMA) Nathalie Bere Patient Relations Public Engagement Department EMA Training Day 29 November, 2016 An agency of the European Union What is the European Medicines Agency

More information

DIRECTIVES. (Text with EEA relevance)

DIRECTIVES. (Text with EEA relevance) L 238/44 DIRECTIVES COMMISSION DIRECTIVE (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of

More information

(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use

(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing authorisation

More information

The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,

The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn, The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first

More information

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines

More information

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1 1. Introduction Draft Guidance for Pharmacists on Extemporaneous Dispensing Version 1 The purpose of this guidance is to assist pharmacists in discharging their legal and professional obligations to patients

More information

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893 COUNCIL OF THE EUROPEAN UNION Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DLEG 51 CODEC 893 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: Common Position with

More information

Consultation Strategy. Impact Assessment on an initiative to limit industrial trans fats intakes in the EU

Consultation Strategy. Impact Assessment on an initiative to limit industrial trans fats intakes in the EU Consultation Strategy Impact Assessment on an initiative to limit industrial trans fats intakes in the EU 1. Context and background Trans fatty acids (also called "trans fats" and abbreviated as TFAs)

More information

Falsified Medicines Directive - Safety Features Update

Falsified Medicines Directive - Safety Features Update Falsified Medicines Directive - Safety Features Update Catherine Neary GMP Conference 12 th November 2014 Agenda Background Delegated Act(s) Proposals Under Consideration White List & Black List Next Steps

More information

EPF s response to the European Commission s public consultation on the "Summary of Clinical Trial Results for Laypersons"

EPF s response to the European Commission s public consultation on the Summary of Clinical Trial Results for Laypersons EPF s response to the European Commission s public consultation on the "Summary of Clinical Trial Results for Laypersons" August 2016 This document received funding under an operating grant from the European

More information

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10.12.2008 COM(2008) 664 final 2008/0257 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending, as regards pharmacovigilance

More information

Maltese Presidency of the Council of the European Union. Ministry for Health

Maltese Presidency of the Council of the European Union. Ministry for Health Maltese Presidency of the Council of the European Union Ministry for Health The Trio programme Guided by the strategic agenda of the European Council adopted in June 2014 One of the common priority areas

More information

MEDICINES ADHERENCE The Role of the Pharmacist

MEDICINES ADHERENCE The Role of the Pharmacist BROUGHT TO YOU BY MEDICINES ADHERENCE The Role of the Pharmacist Developed by Pfizer 15 May, 2017 This learning module is intended for UK healthcare professionals only. Job code; PP-GEP-GBR-0682. Date

More information

A response by Servier to the Decision Support Unit report on strontium ranelate

A response by Servier to the Decision Support Unit report on strontium ranelate A response by Servier to the Decision Support Unit report on strontium ranelate Servier gratefully acknowledges the report from the DSU on the appraisal of strontium ranelate for the prevention of osteoporotic

More information

Summary 1. Comparative effectiveness of sapropterin dihydrochloride

Summary 1. Comparative effectiveness of sapropterin dihydrochloride Cost-effectiveness of sapropterin dihydrochloride (Kuvan ) for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown

More information

POSITION PAPER PALLIATIVE CARE, PEDIATRIC PALLIATIVE CARE AND PAIN THERAPY: HUMANIZATION OF CARE

POSITION PAPER PALLIATIVE CARE, PEDIATRIC PALLIATIVE CARE AND PAIN THERAPY: HUMANIZATION OF CARE POSITION PAPER 1 PALLIATIVE CARE, PEDIATRIC PALLIATIVE CARE AND PAIN THERAPY: HUMANIZATION OF CARE GROUP LEADER: Basilicata Region OTHER PARTNERS: Calabria; Campania; Lazio; Marche; Piemonte; Prov. Aut.

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE RNI Conseil 2017 Tous droits réservés Toute reproduction interdite sans l'autorisation de l'auteur. KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE Anne Laure TARDY, PhD

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 26 July 2006 Doc. Ref. EMEA/186279/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON LEGAL STATUS FOR THE SUPPLY TO THE PATIENT OF CENTRALLY AUTHORISED

More information

Harmonized Salt Iodization future policy approach to achieve the mission and vision in eliminating Iodine deficiency in Europe

Harmonized Salt Iodization future policy approach to achieve the mission and vision in eliminating Iodine deficiency in Europe Harmonized Salt Iodization future policy approach to achieve the mission and vision in eliminating Iodine deficiency in Europe Introduction Brussels, 01.11.2017 The joint WHO and UNICEF report published

More information

Additional monitoring of medicines and direct patient reporting impact on the package leaflet

Additional monitoring of medicines and direct patient reporting impact on the package leaflet Additional monitoring of medicines and direct patient reporting impact on the package leaflet EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) - 30 th November

More information

European standard setting via CEN TC 437

European standard setting via CEN TC 437 European standard setting via CEN TC 437 Global forum on Nicotine 2015 CEN-CENELEC Alberto Simeoni Innovation Dept. GFN 2015 Warsaw, 5 June 2015 EUROPEAN STANDARDIZATION ORGANIZATIONS European Committee

More information

Wyss Zürich Regulatory Affairs Seminar

Wyss Zürich Regulatory Affairs Seminar Wyss Zürich Regulatory Affairs Seminar Hospital Exemption & Compassionate Use EU Framework Catherine Longeval Koen T Syen Zürich, 5 July 2017 1 Table of contents Introduction Hospital Exemption Implementation

More information

Update on the revision of the new package leaflet (PL) template. An agency of the European Union

Update on the revision of the new package leaflet (PL) template. An agency of the European Union Update on the revision of the new package leaflet (PL) template An agency of the European Union Contents Regulatory background New QRD package leaflet template -Origin - Contents and structure 2 Regulatory

More information

Specific Challenges for Orphan Drugs with Paediatric Development

Specific Challenges for Orphan Drugs with Paediatric Development Specific Challenges for Orphan Drugs with Paediatric Development Tsveta Schyns-Liharska, PhD ENRAH Member of the PDCO, EMA Representing Patients and EURORDIS Disclaimer Some of the slides in this presentation

More information

Proposal 1 Do you agree with the proposal to report Traded Options when matched on the market data feed LMEselectMD?

Proposal 1 Do you agree with the proposal to report Traded Options when matched on the market data feed LMEselectMD? Appendix 1 Summary of Feedback and Responses Proposal 1 Do you agree with the proposal to report Traded Options when matched on the market data feed LMEselectMD? Respondent 1 The respondent is in favour

More information

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope IPEC Europe Observations and Recommendations on Guidelines On The Formalised Risk Assessment For Ascertaining The Appropriate Good Manufacturing Practice For Excipients Of Medicinal Products For Human

More information

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Proposal in response to EFPIA paper of 3 rd October 2014 EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Presented by Sabine Brosch (EMA) and Anja van

More information

Pharmacies in Europe: Trends and Developments. Dr Jan Smits

Pharmacies in Europe: Trends and Developments. Dr Jan Smits Pharmacies in Europe: Trends and Developments Dr Jan Smits Members: Professional Bodies & Pharmacists Associations Who does PGEU represent? PGEU members are national associations & professional bodies

More information

Assessing benefit/risk of medicinal products

Assessing benefit/risk of medicinal products Assessing benefit/risk of medicinal products Regulatory framework and legal implications Professor Vincenzo Salvatore Head of Legal Service London, BIICL, 29 September 2010 An agency of the European Union

More information

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment

More information

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements

More information

Outline. Bioethics in Research and Publication. What is ethics? Where do we learn ethics? 6/19/2015

Outline. Bioethics in Research and Publication. What is ethics? Where do we learn ethics? 6/19/2015 Outline Bioethics in Research and Publication Gertrude Night, PhD Rwanda Agriculture Board What is ethics? History. The purpose of training in research ethics Some ethical principles addressed by research

More information

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations LAB 13 Expression of opinions & interpretations UKAS Guidance on the Application of ISO/IEC 17025 Dealing with Expressions of Opinions and Interpretations [UKAS Publication ref: LAB 13] Contents Section

More information

Frequently asked questions

Frequently asked questions 13 February 2017 EMA/527628/2011 Rev. 1 Directorate This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question

More information

A regulatory perspective What do I want to know?

A regulatory perspective What do I want to know? A regulatory perspective What do I want to know? June M Raine MHRA, UK 11 December 2017 What does regulator want to know? Regulatory decision-making responsibilities Answering the regulatory questions

More information

GENERAL COMMENTS. The Task Force Process Should be Fully Open, Balanced and Transparent

GENERAL COMMENTS. The Task Force Process Should be Fully Open, Balanced and Transparent December 9, 2013 Submitted Electronically United States Preventive Services Task Force c/o Dr. Robert Cosby Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 RE: USPSTF Draft

More information

Guideline on the acceptability of names for human medicinal products processed through the centralised procedure

Guideline on the acceptability of names for human medicinal products processed through the centralised procedure 1 2 3 07 June 2013 CPMP/328/98, Revision 6 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the acceptability of names for human medicinal products processed through the centralised

More information

Improving new drug development for paediatric cancer: the EMA and PDCO vision

Improving new drug development for paediatric cancer: the EMA and PDCO vision Dr. Dirk Mentzer, MD, PhD Consultant General Paediatrics Head of Pharmacovigilance unit Chair of PDCO at EMA Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, Germany Disclaimer The

More information

PRAC non-interventional imposed PASS final study report assessment report

PRAC non-interventional imposed PASS final study report assessment report 1 December 2016 EMA/101714/2017 Pharmacovigilance Risk Assessment Committee (PRAC) PRAC non-interventional imposed PASS final study report assessment report Active substance: cyproterone/ethinylestradiol

More information

Quality, Safety and Sourcing in Unlicensed Medicines

Quality, Safety and Sourcing in Unlicensed Medicines Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?

More information

Declaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018

Declaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018 Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects

More information

Report. Uganda Pharmaceutical Sector Scan JUNE 2010

Report. Uganda Pharmaceutical Sector Scan JUNE 2010 Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.

More information

Changing the prevention paradigm for the future what Europe can do

Changing the prevention paradigm for the future what Europe can do November 3rd, 2014 Honorable Beatrice Lorenzin, Minister of Health of Italy Italian Presidency of the EU Council Conference/Meeting The State of Health of Vaccination in the EU: where do we stand, where

More information